Accession NumberDB00225  (APRD00990)
TypeSmall Molecule

Gadodiamide is a gadolinium based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. It is commonly marketed under the trade name Omniscan.

Gadodiamide anhydrous
External IDs S-041
Product Ingredients
IngredientUNIICASInChI KeyDetails
Gadodiamide hydrate0RPE15QPL0 122795-43-1XPCLDSMKWNNKOM-UHFFFAOYSA-KDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OmniscanSolution287 mgIntravenousGe Healthcare1997-03-25Not applicableCanada
OmniscanInjection287 mg/mLIntravenousGe Healthcare2002-04-19Not applicableUs
OmniscanInjection287 mg/mLIntravenousGe Healthcare2005-07-29Not applicableUs
Omniscan Liq IV 287mg/mlLiquid287 mgIntravenousSanofi1994-12-311997-07-30Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CAS number131410-48-5
WeightAverage: 573.66
Monoisotopic: 574.10225
Chemical FormulaC16H26GdN5O8

For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, gadodiamide shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, gadodiamide primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Gadodiamide does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadodiamide in lesions such as neoplasms, abscesses, and subacute infarcts.

Related Articles
AbsorptionNot Available
Volume of distribution
  • 200 ± 61 mL/kg
Protein bindingNot Available

There is no detectable biotransformation or decomposition of gadodiamide.

Route of elimination

Gadodiamide is eliminated primarily in the urine.

Half life

Two-compartment model with mean distribution and elimination half-lives (reported as mean ± SD) of 3.7 ± 2.7 minutes and 77.8 ± 16 minutes, respectively.

  • Renal cl=1.7 mL/min/kg
  • Plasma cl=1.8 mL/min/kg
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Drug Interactions Not Available
Food InteractionsNot Available
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesV08CA03 — Gadodiamide
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (56.3 KB)
Clinical Trials
Clinical Trials
3CompletedDiagnosticAnatomic renal artery stenosis1
3CompletedDiagnosticAorto-Iliac Stenosis / Arterial Occlusive Diseases1
4CompletedNot AvailableChronic Kidney Disease (CKD) / Impaired Renal Function1
  • Ge healthcare
Dosage forms
InjectionIntravenous287 mg/mL
SolutionIntravenous287 mg
LiquidIntravenous287 mg
Unit descriptionCostUnit
Omniscan prefill plus syringe7.02USD ml
Omniscan 287 mg/ml vial6.98USD ml
Omniscan 287 mg/ml bottle6.49USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1335819 No1995-06-062012-06-06Canada
US5362475 No1994-11-082011-11-08Us
US5560903 No1993-10-012013-10-01Us
Experimental PropertiesNot Available
Predicted Properties
Physiological Charge3ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area171.24 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity122.25 m3·mol-1ChemAxon
Polarizability40.72 Å3ChemAxon
Number of Rings7ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Human Intestinal Absorption-0.9808
Blood Brain Barrier+0.62
Caco-2 permeable-0.5605
P-glycoprotein substrateSubstrate0.7041
P-glycoprotein inhibitor INon-inhibitor0.9016
P-glycoprotein inhibitor IINon-inhibitor0.9571
Renal organic cation transporterNon-inhibitor0.9031
CYP450 2C9 substrateNon-substrate0.8265
CYP450 2D6 substrateNon-substrate0.8189
CYP450 3A4 substrateNon-substrate0.5872
CYP450 1A2 substrateNon-inhibitor0.9416
CYP450 2C9 inhibitorNon-inhibitor0.9189
CYP450 2D6 inhibitorNon-inhibitor0.9566
CYP450 2C19 inhibitorNon-inhibitor0.8972
CYP450 3A4 inhibitorNon-inhibitor0.9864
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9927
Ames testNon AMES toxic0.8343
BiodegradationNot ready biodegradable0.7604
Rat acute toxicity1.9159 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9582
hERG inhibition (predictor II)Non-inhibitor0.9424
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Mass Spec (NIST)Not Available
SpectraNot Available
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid amides
Alternative ParentsAlpha amino acids / Tricarboxylic acids and derivatives / Trialkylamines / Secondary carboxylic acid amides / Carboxylic acid salts / Amino acids / Carboxylic acids / Organic zwitterions / Organic salts / Organic oxides
SubstituentsAlpha-amino acid amide / Alpha-amino acid / Tricarboxylic acid or derivatives / Carboxamide group / Carboxylic acid salt / Secondary carboxylic acid amide / Tertiary amine / Tertiary aliphatic amine / Amino acid / Carboxylic acid
Molecular FrameworkAliphatic acyclic compounds
External Descriptorsgadolinium coordination entity (CHEBI:37333 )
Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:46